enVVeno Medical stock analysis
Want to see NVNO full AI Analyst Report?
enVVeno Medical (NVNO) Stock Price & Analysis
NVNO Stock Chart & Stats
- Day’s Range
- $5.43 - $5.85
- 52-Week Range
- $5.43 - $14.69
- Previous Close
- $5.77
- Volume
- N/A
- Average Volume (3M)
- 36.12K
- Market Cap
- $3.87M
- Enterprise Value
- -$12.65M
- Total Cash (Recent Filing)
- $18.47M
- Total Debt (Recent Filing)
- $408.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.82
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces fixed financial obligations and preserves balance-sheet flexibility while the company advances its device programs. This can provide greater capacity to fund development and absorb setbacks than a similarly loss-making business with substantial debt.
Sustained Clinical Benefit
Three-year clinical improvements support the durability of VenoValve’s therapeutic benefit rather than a short-lived response. Sustained reductions in disease severity and improvements in symptoms and quality of life could strengthen physician adoption and future commercial credibility.
Next-generation Product Pipeline
The FDA-authorized TAVVE study advances enVVe, a less invasive replacement valve designed for light sedation and same-day discharge. If clinical development succeeds, this product could broaden procedural accessibility and extend the company’s opportunity beyond open-surgery VenoValve.
Bears Say
No Commercial Revenue
The absence of reported revenue shows that the company has not yet converted its technology into a commercial business. Until product approval, launch and adoption occur, financial performance remains dependent on clinical progress rather than recurring customer demand or operating scale.
Persistent Cash Burn
Continued negative operating and free cash flow means the business cannot currently fund operations from internally generated cash. The stated dependence on external funding may create dilution or financing pressure and could constrain development if capital becomes harder to secure.
Equity Erosion And Losses
Material equity erosion indicates that accumulated losses have reduced the company’s financial base over time. Without a transition to profitability, further deficits or financing needs could continue diluting shareholder value and limit resources available for commercial execution.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
What is enVVeno Medical’s market cap?
When is enVVeno Medical’s upcoming earnings report date?
How were enVVeno Medical’s earnings last quarter?
Is enVVeno Medical overvalued?
Does enVVeno Medical pay dividends?
What is enVVeno Medical’s EPS estimate?
How many shares outstanding does enVVeno Medical have?
What happened to enVVeno Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of enVVeno Medical?
What is the TipRanks Smart Score and how is it calculated?
Company Description
enVVeno Medical
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert A. Berman
- Employees
- 33
- Website
- www.envveno.com
- Address
- 70 Doppler, Irvine, CA, 92618, US
enVVeno Medical (NVNO) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 0 | 15 |
| Technical Analysis | 7 | 0 | 3 |
| Moving Averages | 0 | 0 | 12 |










